GlassScriptPhysician profile
Gary L Penny
NPI 1184738643
$6,170.25
in general payments reported to CMS, 2019-2025
25 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $953 · 2021: $1,087 · 2022: $918 · 2023: $893 · 2024: $849 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.28 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $777.63 | 2019-2025 | Rexulti, Nuedexta |
| Avanir Pharmaceuticals, INC. | $627.36 | 2019-2022 | |
| Eisai INC. | $523.69 | 2020-2021 | |
| Allergan, INC. | $389.53 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $363.02 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $343.13 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $338.86 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $314.26 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $235.17 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $221.66 | 2019-2021 | |
| Bausch Health US, LLC | $181.24 | 2019-2024 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $167.25 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $131.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $112.05 | 2022-2024 | Auvelity |
| Alkermes, INC. | $85.93 | 2023 | Aristada, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $53.85 | 2022 | |
| Arbor Pharmaceuticals, INC. | $50.97 | 2021 | |
| Merck Sharp & Dohme LLC | $42.46 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $35.30 | 2021 | |
| Brainsway USA INC | $28.12 | 2022 | |
| Livanova USA, INC. | $24.67 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.79 | 2021 | |
| Shire North American Group INC | $17.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Penny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.